You are here: Industry Insights > Vedanta

News List

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo pharmaceutical-business-review
December 16, 2019
Vedanta Biosciences announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune ...
Vedanta Biosciences gets CARB-X grant to develop anti-infective pharmaceutical-technology
December 09, 2019
Vedanta Biosciences has received a research grant from CARB-X to support the development of an anti-infective to treat hospital-acquired infections by multi-drug resistant organisms (MDRO).
Vedanta nets $27M to move microbiome assets through the clinic fiercebiotech
January 07, 2019
Barely a month after Vedanta Biosciences collected a $12 million payment from Johnson & Johnson, the biotech raised another $27 million in its series C round.....
PureTech’s Vedanta raises $27m for microbiome research pharmaphorum
December 25, 2018
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy.
Bristol-Myers and Vedanta to study combination therapy for cancer pharmaceutical-technology
December 12, 2018
Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate for the treatment of advanced or metastatic cancers.